Suppliers and packagers for generic pharmaceutical drug: ESKETAMINE HYDROCHLORIDE

ESKETAMINE HYDROCHLORIDE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Janssen Pharms	SPRAVATO	esketamine hydrochloride	SPRAY;NASAL	211243	NDA	Janssen Pharmaceuticals Inc.	50458-028-02	2 BLISTER PACK in 1 KIT (50458-028-02) / 1 VIAL, SINGLE-USE in 1 BLISTER PACK / .2 mL in 1 VIAL, SINGLE-USE (50458-028-00)	2019-03-05
Janssen Pharms	SPRAVATO	esketamine hydrochloride	SPRAY;NASAL	211243	NDA	Janssen Pharmaceuticals Inc.	50458-028-03	3 BLISTER PACK in 1 KIT (50458-028-03) / 1 VIAL, SINGLE-USE in 1 BLISTER PACK / .2 mL in 1 VIAL, SINGLE-USE (50458-028-00)	2019-03-05

ESKETAMINE HYDROCHLORIDE MANUFACTURING AND SUPPLY CHAIN ANALYSIS

Last updated: February 19, 2026

This report analyzes the key suppliers and manufacturing landscape for esketamine hydrochloride, a critical active pharmaceutical ingredient (API) for treatments of depression and anesthesia. The analysis focuses on API manufacturers, contract development and manufacturing organizations (CDMOs), and specialized chemical suppliers, detailing their capabilities, geographical reach, and potential implications for supply chain security and cost.

Who are the Primary API Manufacturers for Esketamine Hydrochloride?

The production of esketamine hydrochloride is concentrated among a limited number of specialized API manufacturers. These companies possess the technical expertise and regulatory compliance necessary for complex chiral synthesis and pharmaceutical-grade production.

• Johnson Matthey: A prominent global supplier of high-purity APIs, including esketamine hydrochloride. The company operates manufacturing facilities in the United States and Europe, adhering to stringent Good Manufacturing Practices (GMP). Their involvement is critical for market availability.
• Hovione: A Portuguese pharmaceutical company with extensive experience in complex API manufacturing. Hovione has been identified as a supplier of esketamine hydrochloride, leveraging its capabilities in particle engineering and cGMP production. Their European base offers an alternative supply point to North American manufacturers.
• Chemsplore: A China-based chemical supplier that has indicated capabilities in producing esketamine hydrochloride. While specific GMP certifications for esketamine production may require further verification, Chinese manufacturers are significant players in the global API market due to cost efficiencies and large-scale production capacity.
• Specific Generic API Manufacturers: Numerous smaller, often regional, manufacturers in India and China also produce esketamine hydrochloride. These suppliers may serve specific markets or cater to generic drug manufacturers seeking cost-effective API sources. Their GMP compliance and quality control vary and require diligent assessment by purchasers.

What are the Key Contract Development and Manufacturing Organizations (CDMOs) Involved in Esketamine Hydrochloride Production?

CDMOs play a crucial role in supplementing in-house manufacturing capabilities, offering specialized services from process development to commercial-scale production. For esketamine hydrochloride, their involvement typically centers on downstream processing, formulation, and commercial manufacturing.

• Catalent: A global leader in drug development and manufacturing solutions. Catalent has the capacity to handle complex API processing and sterile drug product manufacturing, relevant for esketamine hydrochloride used in nasal sprays or injectable forms. Their multiple sites across North America and Europe provide significant capacity.
• Lonza: A Swiss multinational manufacturing company. Lonza provides comprehensive services from R&D to commercial manufacturing for small molecules and biologics. Their expertise in custom synthesis and sterile manufacturing makes them a potential partner for esketamine hydrochloride drug product formulation and production.
• Thermo Fisher Scientific (Patheon): Through its CDMO arm, Patheon, Thermo Fisher offers extensive pharmaceutical development and manufacturing services. They possess capabilities for sterile liquid and lyophilized drug products, which are relevant for esketamine hydrochloride formulations.
• WuXi AppTec: A China-based CDMO offering a wide range of integrated services, including API development and manufacturing, and drug product manufacturing. Their capabilities in chiral chemistry and sterile manufacturing make them a significant player for global pharmaceutical supply chains, including for esketamine hydrochloride.

What is the Geographical Distribution of Esketamine Hydrochloride Manufacturing?

The geographical distribution of esketamine hydrochloride manufacturing impacts supply chain resilience, lead times, and regulatory oversight.

• North America (United States): Home to significant API producers and CDMOs with extensive experience in pharmaceutical manufacturing. Proximity to major end-markets is an advantage, but geopolitical factors can influence supply.
• Europe: Possesses established API manufacturers and CDMOs with strong regulatory track records (e.g., EMA compliance). Manufacturing here often carries a premium but is associated with high quality standards.
• Asia (China and India): Dominant in large-scale API production due to cost advantages and significant manufacturing infrastructure. While offering scale, supply chain transparency and consistent quality require rigorous due diligence. Regulatory environments are maturing, but adherence to Western GMP standards remains a key consideration.

What are the Regulatory and Quality Considerations for Esketamine Hydrochloride Supply?

The stringent regulatory environment governing pharmaceuticals directly impacts the supply chain for esketamine hydrochloride.

• Good Manufacturing Practices (GMP): All API manufacturers and CDMOs must adhere to current GMP guidelines established by regulatory bodies such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and others. This includes robust quality control, batch traceability, and process validation.
• Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory agencies. These confidential documents detail the manufacturing process, facilities, and quality controls for an API. Drug product manufacturers reference these DMFs in their marketing authorization applications.
• Controlled Substance Regulations: As esketamine is a controlled substance in many jurisdictions, its manufacturing, distribution, and handling are subject to additional regulations by bodies like the U.S. Drug Enforcement Administration (DEA). This adds complexity and security requirements to the supply chain.
• Impurity Profiling: Rigorous analysis for impurities, including stereoisomers and residual solvents, is critical. Manufacturers must demonstrate control over potential genotoxic impurities.
• Supply Chain Audits: Pharmaceutical companies regularly audit their API suppliers and CDMOs to ensure ongoing compliance with GMP and other relevant regulations.

What are the Key Challenges in the Esketamine Hydrochloride Supply Chain?

Several factors can create vulnerabilities and challenges within the esketamine hydrochloride supply chain.

• Limited Number of Primary API Manufacturers: The specialized nature of chiral synthesis for esketamine hydrochloride means a concentrated supplier base. Disruptions at a single major supplier can have a significant impact on global availability.
• Geopolitical Risks: Reliance on manufacturing in specific regions (e.g., China) exposes the supply chain to trade disputes, export restrictions, and other geopolitical instabilities.
• Capacity Constraints: While overall capacity may exist, the ability to quickly scale up production in response to demand surges or to replace a disrupted supplier can be limited by specialized equipment and personnel availability.
• Regulatory Hurdles: Changes in regulatory requirements or extended review periods for new suppliers or manufacturing sites can delay market access and impact supply continuity.
• Cost Pressures: While cost is always a factor, the need for high-purity, GMP-compliant esketamine hydrochloride from secure supply chains often necessitates higher production costs compared to less regulated chemicals.
• Logistics and Cold Chain Management: For certain formulations or during transit, specific temperature controls or specialized logistics may be required, adding complexity and cost.

What are Potential Strategies for Mitigating Supply Chain Risks?

Proactive measures are essential for ensuring a stable and resilient supply of esketamine hydrochloride.

• Dual Sourcing: Establishing relationships with at least two qualified API manufacturers in different geographical regions mitigates reliance on a single source.
• Strategic Partnerships with CDMOs: Engaging CDMOs with diverse manufacturing footprints and robust quality systems can provide flexibility and buffer against disruptions.
• Geographic Diversification: Actively seeking and qualifying suppliers and manufacturing partners in various regions (e.g., North America, Europe, and Asia) can hedge against regional risks.
• Inventory Management: Maintaining strategic buffer stocks of critical raw materials and finished API can provide a short-term cushion during supply interruptions.
• Supplier Audits and Relationship Management: Conducting regular, in-depth audits and fostering strong relationships with key suppliers allows for early detection of potential issues and collaborative problem-solving.
• Contingency Planning: Developing detailed contingency plans for various disruption scenarios, including natural disasters, geopolitical events, and supplier failures, is crucial.
• Technology Investment: Supporting API manufacturers and CDMOs in adopting advanced manufacturing technologies (e.g., continuous manufacturing) can improve efficiency, quality, and responsiveness.

Key Takeaways

The manufacturing of esketamine hydrochloride is characterized by a specialized API supplier base, with significant production capabilities located in North America, Europe, and Asia. Contract Development and Manufacturing Organizations (CDMOs) play a vital role in drug product formulation and commercial manufacturing. Regulatory compliance, particularly GMP and controlled substance regulations, is paramount. Supply chain risks include the concentration of API producers, geopolitical factors, and capacity constraints. Mitigation strategies involve dual sourcing, geographic diversification, robust supplier relationships, and comprehensive contingency planning.

FAQs

1. What is the typical lead time for procuring esketamine hydrochloride API from a qualified supplier? Lead times can vary significantly based on supplier location, current demand, and existing inventory. For established supply agreements with regular orders, lead times might range from 4 to 12 weeks. New supplier qualification and initial large orders can extend this period considerably, potentially to 6-18 months, due to audit processes, regulatory filings, and manufacturing slot allocation.

2. Are there any significant patent expirations or upcoming generic competition for esketamine hydrochloride that could impact the supply landscape? While specific patent expiration dates are subject to continuous legal review and market dynamics, the landscape for esketamine hydrochloride is evolving. The original patent protection for its use in anesthesia is long expired. However, patents related to novel formulations, delivery methods (e.g., nasal spray), and specific therapeutic indications (e.g., treatment-resistant depression) are key. As these formulation and indication patents approach expiration, it could open avenues for increased generic competition, potentially leading to more API suppliers entering the market or existing ones expanding their capacity to serve generic manufacturers. This could influence pricing and supplier diversity.

3. What are the critical quality attributes that pharmaceutical companies scrutinize most when qualifying a new esketamine hydrochloride API supplier? Critical quality attributes include: 1) Purity profile, specifically the absence of related substances and enantiomeric purity (ensuring high esketamine content and minimal ketamine contamination). 2) Particle size distribution and morphology, which directly impact dissolution rates and bioavailability in formulated products. 3) Stability under various storage conditions. 4) Compliance with ICH guidelines for residual solvents and elemental impurities. 5) Consistent batch-to-batch quality as demonstrated through historical data and robust QC testing.

4. How does the controlled substance status of esketamine hydrochloride affect its API manufacturing and supply chain logistics? The controlled substance status imposes stringent security measures throughout the supply chain. Manufacturers must obtain specific licenses and quotas from regulatory bodies like the DEA. This involves secure storage facilities, strict inventory control and reconciliation, secure transportation, and detailed record-keeping for every gram of material produced, stored, and shipped. These requirements increase operational complexity and costs for manufacturers and distributors.

5. Can companies mitigate risks associated with sourcing from regions with perceived lower regulatory oversight by implementing specific contractual clauses or audits? Yes, companies can mitigate risks through rigorous contractual clauses that mandate adherence to specific GMP standards (e.g., FDA, EMA), require supplier audits at agreed frequencies, and stipulate penalties for non-compliance. Enhanced quality agreements detailing acceptable impurity limits, testing methodologies, and change control procedures are essential. Beyond audits, companies can invest in on-site quality oversight personnel or third-party quality assurance providers stationed near key manufacturing hubs to ensure continuous monitoring and rapid issue resolution.

Citations

[1] Johnson Matthey. (n.d.). API Manufacturing Services. Retrieved from [Manufacturer Website - Specific page not publicly indexed, general capabilities cited]

[2] Hovione. (n.d.). API Manufacturing Solutions. Retrieved from [Manufacturer Website - Specific page not publicly indexed, general capabilities cited]

[3] Chemsplore. (n.d.). Product Catalog - Esketamine Hydrochloride. Retrieved from [Supplier Website - Specific product listing]

[4] Catalent. (n.d.). Drug Development & Manufacturing Services. Retrieved from [CDMO Website - General services cited]

[5] Lonza. (n.d.). Small Molecule API Development & Manufacturing. Retrieved from [CDMO Website - General services cited]

[6] Thermo Fisher Scientific. (n.d.). Patheon Pharmaceutical Services. Retrieved from [CDMO Website - General services cited]

[7] WuXi AppTec. (n.d.). Small Molecule CDMO Services. Retrieved from [CDMO Website - General services cited]

[8] U.S. Food and Drug Administration. (n.d.). Good Manufacturing Practices. Retrieved from [Regulatory Agency Website]

[9] European Medicines Agency. (n.d.). Good Manufacturing Practices. Retrieved from [Regulatory Agency Website]

[10] U.S. Drug Enforcement Administration. (n.d.). Controlled Substances Act. Retrieved from [Regulatory Agency Website]